Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB825 in Adults With Atopic Dermatitis
NCT05059509Phase 2Completed
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Feb 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of FB825 in atopic dermatitis (AD), sponsored by Oneness Biotech Co., Ltd.. Started Feb 2020; status: completed.
02
Drugs
FB825
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05059509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059509.